Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Genentech, Takeda Oncology, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma

18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma


Agenda

Friday, February 14, 2014
7:00 am Registration and Breakfast  
8:00 am Welcome Andrew Zelenetz, MD, PhD
Multiple Myeloma
8:15 am Genomics in multiple myeloma - what have we learned? Leif Bergsagel, MD
8:35 am High-risk smoldering myeloma - what should we do? Ola Landgren, MD
8:55 am High-risk multiple myeloma - how do we define and manage? Keith Stewart, MD
9:15 am Landscape of treatment for relapsed multiple myeloma James Berenson, MD
9:45 am Break  
Leukemia #1 (CML/MPNs)
10:05 am Which TKI should be used as initial therapy for patients in chronic phase, considering the longer term toxicities recently described with "second generation" TKIs? Charles Schiffer, MD
10:25 am Should therapy be switched in patients in chronic phase who fail to achieve a transcript level below 10% (IS) after 3 months of treatment with imatinib? Harry Erba, MD, PhD
10:40 am Is there evidence for the use of prophylactic antibiotics and antifungal agents during the treatment of acute leukemia? Susan Seo, MD
11:05 am The benefits and limitations of therapy with JAK2 inhibitors Reuben A. Mesa, MD, FACP
12:05 pm Lunch  
Lymphoma #1
1:20 pm Lymphoma classification and impact of genomics Randy Gascoyne, MD
1:40 pm Is cell of origin important in the primary management of DLBCL? John P. Leonard, MD
2:00 pm Beyond high dose therapy - management of relapsed/refractory DLBCL
Faculty has not granted permission to post this presentation
Anas Younes, MD
2:20 pm CNS lymphoma - state of the art
Faculty has not granted permission to post this presentation
Lisa DeAngelis, MD
2:40 pm Panel Q&A
Faculty has not granted permission to post this presentation
 
2:50 pm Break  
CLL
3:10 pm Receptor pathways to target for CLL therapy Jennifer Brown, MD
3:30 pm Anti-apoptotic protein as therapeutic target in CLL Thomas Kipps, MD, PhD
3:50 pm Management of CLL in elderly patients Alessandra Ferrajoli, MD
4:10 pm Emerging important gene mutations in CLL Catherine J. Wu, MD
4:30 pm Panel Q&A  
Case Discussion #2
4:40 pm 17p del CLL patients - first-line vs relapsed/refractory William Wierda, MD, PhD
5:00 pm Adjourn  
     
5:30 pm - 6:30pm Reception Broadway Ballroom Act IV
     
Saturday, February 15, 2014
7:00 am Breakfast  
Leukemia #2 (Acute Leukemia/MDS) Moderator: Charles Schiffer, MD
8:00 am Who should be transplanted for ALL in first remission? What is the role of minimal residual disease assessment? Mark R. Litzow, MD
8:20 am Should patients with refractory anemia with excess blasts or those with oligoblastic AML receive induction therapy prior to allogeneic transplantation? Harry Erba, MD, PhD
8:40 am Is there a role for iron chelation therapy in patients with MDS?
Faculty has not granted permission to post this presentation
Virginia Klimek, MD
9:00 am How I manage acute promyelocytic leukemia Martin Tallman, MD
9:20 am Panel Q&A  
9:30 am Break  
Lymphoma #2
9:50 am FL in situ vs partial involvement by FL, MCL in situ Randy Gascoyne, MD
10:10 am Mantle cell lymphoma - new options for therapy Andre Goy, MD
10:30 am Current and future of high-dose therapy in mantle cell lymphoma Issa F. Khouri, MD
10:50 am Management of non-follicular indolent lymphoma Andrew Zelenetz, MD, PhD
11:10 am Panel Q&A  
Case Discussion #1
11:20 am Does molecular characterization of AML help guide therapy? Dan Douer, MD, Harry Ebra, MD, PhD, and Martin Tallman, MD
11:50 am Lunch  
Hodgkin Lymphoma
1:05 pm Molecular prognostication in HL Randy Gascoyne, MD
1:25 pm Debate: Early-stage HL - can radiation be eliminated? NO Joachim Yahalom, MD
1:45 pm Debate: Early-stage HL - can radiation be eliminated? YES John Radford, MD
2:05 pm PET-directed therapy in HL Craig H. Moskowitz, MD
2:25 pm Panel Q&A  
2:35 pm Break  
New Directions in Hematologic Malignancies
2:55 pm Cellular therapy with chimeric antigen receptors in lymphoid malignancies Renier Brentjens, MD, PhD
3:15 pm B cell receptor pathway directed therapy in lymphoid malignancies
Faculty has not granted permission to post this presentation
Anas Younes, MD
3:35 pm Bone health in hematologic malignancies James Berenson, MD
3:55 pm Do hypomethylating agents "really work" via an epigenetic mechanism? Ari Melnick, MD
Case Discussion #2
4:25 pm Lymphoma in the elderly Paul Hamlin, MD, Andre Goy, MD and Craig Moskowitz, MD
4:55 pm Adjourn  







Become a Member

Forgot Password?
Filter By